Wegovy vs Zepbound: Which GLP-1 Is Best for Houston Patients?
Wegovy and Zepbound both work — but they work differently. Here's what Houston-area patients need to know to make the right call with their doctor.
Reviewed for accuracy against current FDA guidance, peer-reviewed clinical trial data (STEP, SURMOUNT trials), and manufacturer prescribing information. See our editorial standards.
Zepbound produces greater average weight loss than Wegovy in clinical trials — roughly 20–22% of body weight versus 15% — but that single data point doesn't settle the question for most Houston patients. The better drug is the one your insurance will actually cover, your body tolerates, and your doctor can get into your hands without a three-month prior authorization battle. Pricing adds another wrinkle: both medications run $1,000-plus per month at retail, and GLP-1 coverage varies widely across Texas employer plans and marketplace policies. This article breaks down the clinical differences between semaglutide and tirzepatide, what real-world costs look like at weight loss clinics in Houston, Sugar Land, and Katy, and how to figure out which option makes sense before your next appointment.
1What Each Drug Actually Is
Wegovy contains semaglutide. It mimics one hormone called GLP-1, which signals your brain that you are full and slows how fast your stomach empties. Novo Nordisk makes it. It was FDA-approved for weight management in June 2021. Zepbound contains tirzepatide. It mimics two hormones: GLP-1 and GIP. That dual action is the key difference. GIP works alongside GLP-1 to further reduce appetite and improve how your body processes fat and sugar. Eli Lilly makes Zepbound. It received FDA approval for weight management in November 2023. Both drugs are self-injected once a week using a prefilled pen. Both follow a dose escalation schedule, meaning you start low and work up over several months to reduce nausea and other side effects. The simple way to think about it: Wegovy hits one target. Zepbound hits two. That distinction matters when you look at the trial data.
2What the Clinical Trials Actually Show
The STEP 1 trial, published in the New England Journal of Medicine in 2021, tested semaglutide 2.4 mg against placebo in adults with obesity. Participants lost an average of 14.9% of their body weight over 68 weeks. That was a landmark result at the time. The SURMOUNT-1 trial, published in the same journal in 2022, tested tirzepatide against placebo. Depending on the dose, participants lost between 15% and 20.9% of their body weight over 72 weeks. The highest dose group averaged a loss of about 48 pounds. No head-to-head trial has directly compared Wegovy and Zepbound in the same study. That matters. You cannot just subtract one percentage from the other and call it a winner. Populations, trial designs, and follow-up periods were different. That said, the SURMOUNT data is consistently stronger in terms of average weight loss. Most obesity medicine physicians in Houston will acknowledge that Zepbound tends to produce greater weight loss on average, especially at higher doses. But individual response varies significantly. Some patients do better on semaglutide. Your results will not be average.
3Side Effects: How They Compare
Both drugs share a similar side effect profile because they both activate GLP-1 receptors. The most common complaints are nausea, vomiting, diarrhea, constipation, and fatigue. These tend to be worst in the first few weeks after a dose increase and usually settle down. In the STEP 1 trial, about 44% of semaglutide patients reported nausea. In SURMOUNT-1, tirzepatide nausea rates ranged from about 17% to 33% depending on the dose group. Some Houston clinicians report that their patients tolerate Zepbound slightly better, possibly because the GIP component softens some of the GI effects. But this is clinical observation, not controlled data. Both drugs carry a boxed warning about a possible risk of thyroid C-cell tumors, based on animal studies. Neither drug is recommended for patients with a personal or family history of medullary thyroid carcinoma or MEN2. Both can slow gastric emptying enough to affect anesthesia, so you need to tell your surgeon if you are on either one before any procedure at Houston Methodist, Memorial Hermann, or anywhere else. Serious side effects are rare but include pancreatitis and gallbladder disease. Your prescribing physician will go over your full history before starting either medication.
4Insurance Coverage in Houston: The Real Story
This is where things get frustrating for a lot of Houston patients. Coverage varies enormously depending on your plan and your employer. On the commercial insurance side, carriers like Blue Cross Blue Shield of Texas, Aetna, United Healthcare, and Cigna all cover one or both medications for some members — but coverage is not automatic. Most require a prior authorization showing a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition like type 2 diabetes, high blood pressure, or sleep apnea. Medicaid in Texas does not currently cover Wegovy or Zepbound for weight loss. Medicare Part D added coverage for Wegovy specifically in 2024 for patients who also have cardiovascular disease, following the SELECT trial results. Zepbound does not yet have that same Medicare indication, though this is an active area of policy change. Many Houston-area employers, including some in the Energy Corridor and the Texas Medical Center, have begun adding GLP-1 coverage to their group plans. It is worth calling your HR department or benefits line directly. Do not assume your plan does not cover it until you have checked. If you are uninsured or your plan excludes these drugs, list price for either medication runs over $1,000 per month without assistance.
5Cost and Savings Programs: What to Know Before You Fill
Cash prices are high for both drugs. Without insurance, Wegovy runs approximately $1,350 per month. Zepbound is priced similarly, around $1,060 to $1,350 per month depending on the dose. Both manufacturers offer savings programs for commercially insured patients who qualify. Novo Nordisk's Wegovy savings card can bring your monthly cost down to as low as $0 for eligible patients, with a cap on annual savings. Eli Lilly offers a similar program for Zepbound, also targeting commercially insured patients. Neither program applies to Medicare or Medicaid enrollees. If you are uninsured, Lilly has a separate direct-to-patient program through their LillyDirect platform. Novo Nordisk has a patient assistance program as well. Both are worth exploring if cost is a barrier. Compounded semaglutide and tirzepatide have circulated widely in Houston, offered through med spas and online telehealth platforms. The FDA has stated that compounded versions are not the same as the approved drugs, and quality control is not guaranteed. Several Houston-area clinics that previously offered compounded GLP-1s have moved away from them following FDA enforcement actions. Ask any clinic you visit whether they are prescribing the brand-name FDA-approved version or a compound. Pharmacies like H-E-B, CVS, and Walgreens locations throughout the Houston metro can fill both prescriptions, though stock shortages have been an ongoing issue.
6Which Drug Do Houston Physicians Tend to Prescribe?
There is no single answer. It depends on the clinic, the physician's training, your insurance, and your medical history. Obesity medicine specialists and endocrinologists in areas like The Woodlands, Pearland, and Bellaire tend to be familiar with both drugs and will discuss your options in detail. Primary care physicians, especially those who do not specialize in weight management, may default to whichever drug their local reps promote or whichever has smoother prior auth processes with your insurance. If you also have type 2 diabetes, the conversation shifts. Ozempic (semaglutide for diabetes) and Mounjaro (tirzepatide for diabetes) are the sister medications to Wegovy and Zepbound. Some physicians prescribe the diabetes versions off-label for weight loss when the weight-loss branded versions are unavailable or when the cost is lower with your insurance. This practice is legal but adds another layer of complexity. A straightforward way to approach your appointment: ask your doctor which drug they have more experience managing, whether your insurance covers both, and whether your health history makes one a better fit. If your plan covers both, trial data gives Zepbound an edge on average weight loss. But if your plan only covers Wegovy, that is the right drug for you.
7Practical Questions to Ask at Your Houston Clinic Visit
Walking into a weight loss clinic in Cypress, Webster, or Humble without a list of questions is a missed opportunity. Here are the questions that actually matter. First, ask whether the clinic accepts your insurance and handles prior authorization in-house. Many clinics in Houston have dedicated staff for this. A clinic that makes you manage your own prior auth is adding stress you do not need. Second, ask what their protocol is if the drug goes on backorder. Shortages have hit both Wegovy and Zepbound at various points. A good clinic will have a plan. Third, ask what monitoring they provide. Blood work, regular check-ins, and nutritional guidance should be part of the program, not add-ons. Fourth, ask about their approach if you hit a plateau. GLP-1 medications work well for most people, but weight loss is not linear. A physician who can adjust your dose, add behavioral support, or discuss combination strategies is more valuable than one who simply refills your prescription. Fifth, ask directly: do they prescribe brand-name FDA-approved medications? This question protects you from compounded products that lack the same quality assurance. Clinics along major corridors like I-10, Highway 290, and the 59/69 Southwest Freeway are easy to find. The quality of care varies widely. Do your homework before you book.
8The Bottom Line: How to Choose
Here is the simple framework. Start with your insurance. Call your carrier or check your benefits portal. Find out which drug is covered, at what tier, and what the prior authorization requirements are. That single step eliminates most of the debate for most patients. If both are covered at similar cost-sharing, Zepbound's SURMOUNT trial data shows greater average weight loss compared to Wegovy's STEP trial data. That is the honest read of the published evidence. But again, these were separate trials with different designs. A direct comparison trial does not yet exist. If cost is the main driver and you are paying out of pocket, compare the current savings card offers from Novo Nordisk and Eli Lilly. Both change periodically. If you have specific health conditions, particularly cardiovascular disease, thyroid history, kidney disease, or gastrointestinal disorders, your physician needs to weigh in before you choose. Do not make this decision based on what your neighbor in Friendswood lost on one drug or the other. Both medications are legitimate, evidence-backed tools. The best one for you is the one you can access, afford, tolerate, and stay on consistently over time.
Houston has no shortage of clinics offering GLP-1 medications. The harder part is finding a physician who will help you choose wisely and stick with you through the process. Use the Houston Weight Loss Directory to find board-certified obesity medicine providers near you — whether you are in Clear Lake, Spring, or Midtown. A good physician makes more difference than the drug name on the label.
Sources & References
Clinical data referenced in this article is drawn from the FDA drug database, peer-reviewed publications (STEP trials, SURMOUNT trials), and manufacturer prescribing information for Wegovy, Ozempic, Zepbound, and Mounjaro. Pricing figures reflect publicly available estimates and may vary. Insurance coverage information is general guidance — confirm your specific benefits with your plan.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a licensed physician before starting any weight loss medication or program.